Molnupiravir

Revisión del 20:28 18 ene 2022 de Rossdonaldson1 (discusión | contribs.) (Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: *Common Trade Names: ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== ===Drug pregnan...")
(difs.) ← Revisión anterior | Revisión actual (difs.) | Revisión siguiente → (difs.)

Administration

  • Type:
  • Dosage Forms:
  • Routes of Administration:
  • Common Trade Names:

Adult Dosing

Pediatric Dosing

Special Populations

Pregnancy Rating

Lactation risk

Renal Dosing

  • Adult:
  • Pediatric:

Hepatic Dosing

  • Adult:
  • Pediatric:

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life:
  • Metabolism:
  • Excretion:

Mechanism of Action

Comments

  • Molnupiravir (Merck)
    • Ages 18 and older only, mild to moderate disease only
    • Within 5 days of symptom onset
    • 800 mg q12hr x 5d
    • Phase 3 trial showed 30% reduction in risk of hospitalization or death
    • Avoid in pregnant or young patients given concern for mutagenicity

See Also

References

Obtenido de «https://www.wikem.org/w/index.php?title=Molnupiravir&oldid=336275»